

AMENDMENTS TO THE CLAIMS

This listing of the claims as amended will replace all prior versions, and listings, of claims in the application.

1-55. **(Canceled)**

56. **(Currently Amended)** A method of treating a subject having rheumatoid arthritis ~~a disorder or condition characterized by an unwanted immune response~~ comprising administering to the subject an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody molecule specifically binds SEQ ID NO:2 ~~to the subject~~.

57-58. **(Canceled)**

59. **(Previously Presented)** The method of claim 56, wherein said depleting anti-CD69 antibody molecule is selected from the group consisting of: a humanized anti-CD69 antibody molecule, a human anti-CD69 antibody molecule, a chimeric anti-CD69 antibody molecule and a deimmunized anti-CD69 antibody molecule.

60. **(Original)** The method of claim 59, wherein said human anti-CD69 antibody molecule is a monoclonal antibody.

61-104. **(Canceled)**

105. **(Currently Amended)** A method of treating a subject having rheumatoid arthritis ~~a disorder or condition characterized by an unwanted immune response~~ comprising administering to the subject an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody molecule specifically binds SEQ ID NO:2 ~~to the subject~~, alone or conjugated to a second therapeutic agent.

106. **(Original)** The method of claim 105, wherein said second therapeutic agent is selected from the group consisting of: chemotherapeutic agents; radioisotopes; and cytotoxins.

107. **(Currently Amended)** The method of claim 105, wherein the antibody molecule is a monoclonal antibody.

108. **(Original)** The method of claim 107, wherein the monoclonal antibody is a human antibody.

109. **(New)** A method of treating a subject having viral chronic hepatitis comprising administering to the subject an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody molecule specifically binds SEQ ID NO:2.

110. **(New)** The method of claim 109, wherein said depleting anti-CD69 antibody molecule is selected from the group consisting of: a humanized anti-CD69 antibody molecule, a human anti-CD69 antibody molecule, a chimeric anti-CD69 antibody molecule and a deimmunized anti-CD69 antibody molecule.

111. **(New)** The method of claim 110, wherein said human anti-CD69 antibody molecule is a monoclonal antibody.

112. **(New)** A method of treating a subject having viral chronic hepatitis comprising administering to the subject an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody molecule specifically binds SEQ ID NO:2, alone or conjugated to a second therapeutic agent.

113. **(New)** The method of claim 112, wherein said second therapeutic agent is selected from the group consisting of: chemotherapeutic agents; radioisotopes; and cytotoxins.

114. **(New)** The method of claim 112, wherein the antibody molecule is a monoclonal antibody.

115. **(New)** The method of claim 114, wherein the monoclonal antibody is a human antibody.